Clinical Trial Update: Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study of BAFF CAR-T cells (LMY-920) for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma is currently recruiting. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• LMY-920

Snippet

Sponsor: Paolo Caimi, MD | Conditions: Relapsed CLL, Refractory CLL | Phase 1 | Status: RECRUITING